Role of HER2/neu in Tumor Progression and Therapy

摘要: HER2 (human epidermal growth factor receptor-2; also known as erbB2) and its relatives HER1 (epidermal receptor; EGFR), HER3 HER4 belong to the HER family of receptor tyrosine kinases. In normal cells, activation this kinase triggers a rich network signaling pathways that control cell growth, differentiation, motility adhesion in several lineages. The first tumor studied for an alteration oncogene is breast carcinoma, so far majority studies have been performed on oncotype. Although involvement cause human transformation needs be further investigated, overexpression carcinomas has associated with more aggressive course disease. It suggested association depends HER2-driven proliferation, vessel formation and/or invasiveness; however, poor prognosis may not directly related presence oncoprotein membrane but instead carcinoma subset identified by characterized peculiar gene expression profile, recently identified. HER2-positive tumors were shown benefit from anthracyclin treatment resistant endocrine therapy. Despite fact many interacting are still fully understood, is, date, promising molecule targeted